Anne Davidson1, Cynthia Aranow, Meggan Mackay. 1. Center for Autoimmunity, Musculoskeletal and Hematologic Diseases, Feinstein Institute for Medical Research, New York, New York, USA.
Abstract
PURPOSE OF REVIEW: The management of lupus nephritis remains unsatisfactory due to insufficiently effective treatment regimens and the dearth of reliable predictors of disease onset or progression to guide individualized therapeutic decisions. This review summarizes new findings related to lupus nephritis over the last 18 months and discusses clinical needs that should be considered to advance trials of mechanism-based therapeutic strategies. RECENT FINDINGS: Collaborative teams are addressing how to improve disease definitions and are developing predictive models for disease onset, disease response and risk of flare in individual patients. More attention is being paid to clinical trial design. Advanced technologic approaches are allowing the analysis of small amounts of human tissue and urine in unprecedented detail so as to discover new pathogenic mechanisms and identify disease biomarkers. Novel therapies continue to be tested in disease models and include new strategies to protect renal tissue from cell damage and fibrosis. SUMMARY: The collaborative efforts of patients, clinical and translational researchers, the pharmaceutical industry and funding sources are needed to advance therapies for lupus nephritis. Specialized clinical centers can then deliver optimal and more personalized patient care that will improve patient outcomes.
PURPOSE OF REVIEW: The management of lupus nephritis remains unsatisfactory due to insufficiently effective treatment regimens and the dearth of reliable predictors of disease onset or progression to guide individualized therapeutic decisions. This review summarizes new findings related to lupus nephritis over the last 18 months and discusses clinical needs that should be considered to advance trials of mechanism-based therapeutic strategies. RECENT FINDINGS: Collaborative teams are addressing how to improve disease definitions and are developing predictive models for disease onset, disease response and risk of flare in individual patients. More attention is being paid to clinical trial design. Advanced technologic approaches are allowing the analysis of small amounts of human tissue and urine in unprecedented detail so as to discover new pathogenic mechanisms and identify disease biomarkers. Novel therapies continue to be tested in disease models and include new strategies to protect renal tissue from cell damage and fibrosis. SUMMARY: The collaborative efforts of patients, clinical and translational researchers, the pharmaceutical industry and funding sources are needed to advance therapies for lupus nephritis. Specialized clinical centers can then deliver optimal and more personalized patient care that will improve patient outcomes.
Authors: B Obrișcă; R Jurubiță; A Andronesi; B Sorohan; C Achim; R Bobeica; M Gherghiceanu; E Mandache; G Ismail Journal: Lupus Date: 2018-05-14 Impact factor: 2.911
Authors: Amanda Mok; Olivia Solomon; Renuka R Nayak; Patrick Coit; Hong L Quach; Joanne Nititham; Amr H Sawalha; Lisa F Barcellos; Lindsey A Criswell; Sharon A Chung Journal: Lupus Sci Med Date: 2016-12-07
Authors: Hannah R Wilson; Nicholas R Medjeral-Thomas; Alyssa C Gilmore; Pritesh Trivedi; Kathleen Seyb; Ramin Farzaneh-Far; Iva Gunnarsson; Agneta Zickert; Thomas D Cairns; Liz Lightstone; H Terence Cook; Matthew C Pickering Journal: Kidney Int Date: 2019-01-14 Impact factor: 10.612
Authors: Vladimir M Liarski; Adam Sibley; Nicholas van Panhuys; Junting Ai; Anthony Chang; Domenick Kennedy; Maria Merolle; Ronald N Germain; Maryellen L Giger; Marcus R Clark Journal: Nat Immunol Date: 2019-02-18 Impact factor: 25.606
Authors: Wesam Gouda; Aldosoky Abd Elaziz Alsaid; Awad Saad Abbas; Tarek M Abdel-Aziz; Mohamed Z Shoaeir; Abd Allah S Abd Elazem; Mohammad Hamdy Sayed Journal: Open Access Rheumatol Date: 2022-09-14